223 related articles for article (PubMed ID: 23262439)
1. JARID1B expression in human melanoma and benign melanocytic skin lesions.
Kuźbicki L; Lange D; Strączyńska-Niemiec A; Chwirot BW
Melanoma Res; 2013 Feb; 23(1):8-12. PubMed ID: 23262439
[TBL] [Abstract][Full Text] [Related]
2. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
3. JARID1B protein expression and prognostic implications in uveal melanoma.
Radberger P; Radberger A; Bykov VJ; Seregard S; Economou MA
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4442-9. PubMed ID: 22669717
[TBL] [Abstract][Full Text] [Related]
4. Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions.
Kuźbicki L; Gajo B; Chwirot BW
Melanoma Res; 2006 Jun; 16(3):235-43. PubMed ID: 16718270
[TBL] [Abstract][Full Text] [Related]
5. Nodal melanocytic nevi in sentinel lymph nodes. Correlation with melanoma-associated cutaneous nevi.
Holt JB; Sangueza OP; Levine EA; Shen P; Bergman S; Geisinger KR; Creager AJ
Am J Clin Pathol; 2004 Jan; 121(1):58-63. PubMed ID: 14750241
[TBL] [Abstract][Full Text] [Related]
6. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.
Prieto VG; Mourad-Zeidan AA; Melnikova V; Johnson MM; Lopez A; Diwan AH; Lazar AJ; Shen SS; Zhang PS; Reed JA; Gershenwald JE; Raz A; Bar-Eli M
Clin Cancer Res; 2006 Nov; 12(22):6709-15. PubMed ID: 17121890
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of RBP2-H1 variant of JARID1B in melanoma.
Kuźbicki Ł; Lange D; Stanek-Widera A; Chwirot BW
BMC Cancer; 2017 Dec; 17(1):854. PubMed ID: 29246117
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC
Am J Pathol; 1995 Mar; 146(3):643-50. PubMed ID: 7534042
[TBL] [Abstract][Full Text] [Related]
9. Cyclin D1 expression in melanocytic lesions of the skin.
Ramirez JA; Guitart J; Rao MS; Diaz LK
Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
11. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors.
Karim RZ; Li W; Sanki A; Colman MH; Yang YH; Thompson JF; Scolyer RA
Int J Surg Pathol; 2009 Oct; 17(5):361-7. PubMed ID: 19666944
[TBL] [Abstract][Full Text] [Related]
12. WT 1 expression in nevi and melanomas: a marker of melanocytic invasion into the dermis.
Garrido-Ruiz MC; Rodriguez-Pinilla SM; Pérez-Gómez B; Rodriguez-Peralto JL
J Cutan Pathol; 2010 May; 37(5):542-8. PubMed ID: 19638168
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase 2 expression in human melanomas and benign melanocytic skin lesions.
Kuźbicki L; Aładowicz E; Chwirot BW
Melanoma Res; 2006 Oct; 16(5):435-44. PubMed ID: 17013093
[TBL] [Abstract][Full Text] [Related]
14. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
15. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand.
Zhuang L; Lee CS; Scolyer RA; McCarthy SW; Zhang XD; Thompson JF; Screaton G; Hersey P
Hum Pathol; 2006 Oct; 37(10):1286-94. PubMed ID: 16949935
[TBL] [Abstract][Full Text] [Related]
16. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
17. The use of elastin immunostain improves the evaluation of melanomas associated with nevi.
Kamino H; Tam S; Tapia B; Toussaint S
J Cutan Pathol; 2009 Aug; 36(8):845-52. PubMed ID: 19032378
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
[TBL] [Abstract][Full Text] [Related]
19. Distribution of muscarinic receptor subtype M3 in melanomas and their metastases.
Oppitz M; Busch C; Garbe C; Drews U
J Cutan Pathol; 2008 Sep; 35(9):809-15. PubMed ID: 18422974
[TBL] [Abstract][Full Text] [Related]
20. A high percentage of skin melanoma cells expresses SPANX proteins.
Salemi M; Calogero AE; Vicari E; Migliore E; Zaccarello G; Cosentino A; Amore M; Tricoli D; Castiglione R; Bosco P; Rappazzo G
Am J Dermatopathol; 2009 Apr; 31(2):182-6. PubMed ID: 19318807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
